ArticleFrontiers in microbiology2022
Antibacterial and anti-biofilm activity of diarylureas against
Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Evaluation of Antibacterial Properties of Nanosuspension of Secondary Metabolites from Streptomyces chrestomyceticus ADP4.Current microbiology · 2026Article
- Multitarget Antibacterial Activity of Novel Aryl-Urea Derivatives Against Vancomycin- and Carbapenem-Resistant Nosocomial Pathogens.Current microbiology · 2026Article
- Next-generation anti-infective drugs in the post-antibiotic era: focusing on anti-virulence agents targeting the bacterial quorum sensing system.Frontiers in cellular and infection microbiology · 2026Review
- Proteomic signatures ofBiofilm · 2025Article
- Antibacterial and antibiofilm activities of kaffir lime essential oils and their active constituents againstHeliyon · 2025Article
- Transcriptome analysis reveals the molecular mechanism of γ-linolenic acid eradicating the biofilm of vancomycin-resistantFrontiers in cellular and infection microbiology · 2025Article
- Novel pentafluorosulfanyl-containing triclocarban analogs selectively kill Gram-positive bacteria.Microbiology spectrum · 2024Article
- The development of thymol-isatin hybrids as broad-spectrum antibacterial agents with potent anti-MRSA activity.RSC medicinal chemistry · 2024Article
- Inhibiting Peptidoglycan Hydrolase Alleviates MRSA Pneumonia Through Autolysin-Mediated MDP-NOD2 Pathway.Infection and drug resistance · 2024Article
- Antimicrobial and antibiofilm effects of essential fatty acids against clinically isolated vancomycin-resistantFrontiers in cellular and infection microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.